News und Analysen

CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the

Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share

Orion (NYSE:OEC), a leading global producer of carbon black, reported its second quarter results on August 6, 2025. The most notable news was that GAAP revenue came in at $466.4 million for Q2 2025

Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that

Seres Therapeutics (NASDAQ:MCRB), a clinical-stage biotech focused on microbiome therapeutics, released its second quarter 2025 earnings on August 6, 2025. The main highlight was a narrowing net

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its

BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue

Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP

Amentum (NYSE:AMTM), a leading provider of engineering, technical, and mission support services to government and commercial customers, reported results for Q3 FY2025 on August 5, 2025. The earnings

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP

Cumberland Pharmaceuticals (NASDAQ:CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology, released its financial results for the second quarter on

Orion Energy Systems (NASDAQ:OESX), a provider of energy-efficient LED lighting and electric vehicle (EV) charging solutions, released its results for the quarter ended June 30, 2025, on August 6

Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from

Geron (NASDAQ:GERN), a biotechnology company focused on therapies for blood disorders, released its second quarter 2025 results on August 6, 2025. The headline news was a sharp acceleration in

Evolus (NASDAQ:EOLS), a performance beauty company specializing in aesthetic neurotoxins and hyaluronic acid (HA) dermal fillers, reported Q2 2025 results on August 5, 2025. The headline news is a

Norwegian Cruise Line Holdings (NYSE: NCLH) benefited from a significant bump following earnings, rising 9% in the following trading session. With record revenue and strength in all three of its

I can actually think of multiple reasons to buy shares of Pfizer (NYSE: PFE) stock, but if I had to focus on only one, I'd choose its dividend. The stock's dividend yield was recently a whopping

Personalis (NASDAQ:PSNL), a precision genomics company focused on ultra-sensitive minimal residual disease (MRD) detection and comprehensive tumor profiling for cancer, reported its second-quarter

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.

Were Vertex's Q2 results

Advanced Micro Devices (NASDAQ:AMD), a leading semiconductor company best known for its processors and graphics cards, released its results on August 5, 2025. The quarter’s headline news was a

Esperion Therapeutics (NASDAQ:ESPR), a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5

ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating